Bronzkori tájakon a Benta völgyében : Kutatások a központ és „hátországa” kapcsolatának megismerésére | Bronze Age Landscapes in the Benta Valley : Research on the Hinterland of Bronze Age Centres

Közép-Európában a bronzkori települések hálózatának és a hozzájuk kapcsolódó temetkezéseknek a kutatása a régészeti terepmunkának mindig is meghatározó irányvonalát alkotta. Az elmúlt évszázadok kutatói elsősorban a nagyobb központi települések, tellek, földvárak megismerését tűzték ki célul. Az utóbbi bő évtizedben alapvető változás kezdődött ezen a területen is. A központi települések tanulmányozása mellett hangsúlyosabbá váltak a mikroregionális kutatások, az eltérő funkciójú és szerkezetű települések és temetkezések vizsgálata. A bronzkori tájhasználat tágan értelmezett kérdéseinek megválaszolására csak komplex kutatási programok vállalkozhatnak. A kutatás során többek között a következő kérdések merülnek fel: 1) Miként definiálhatók regionálisan és mikroregionálisan a bronzkor különböző időszakaiban a települési struktúrák? 2) Léteztek-e valódi központok, specializált települések a bronzkorban Közép-Európában? 3) Hogyan befolyásolta a kulturális háttér az adott régió tájhasználatát? 4) A temetőkben hogyan nyilvánul meg a társadalmi és politikai szerveződés? Ilyen komplex, nemzetközi kutatási programok keretében került sor Százhalombatta vidéke bronzkori településtörténetének vizsgálatára. | Research on the network of Bronze Age settlements and their burial grounds has always been a priority of archaeological fieldwork in Central Europe. Researchers of the past centuries tended to focus on the large central settlements such as tells and hillforts. The past decade has seen a shift in research perspectives: while the study of central settlements has lost none of its importance, interest has grown in micro-regional research and the investigation of settlements with differing function and layout. Only complex research projects can address broad issues of Bronze Age land use. We sought answers to the following questions: 1) Did differences exist between the regional and micro-regional settlement patterns during successive periods of the Bronze Age? 2) Were there genuine centres and specialised settlements during the Bronze Age in Central Europe? 3) How did a communityʼs cultural background influence landscape use in a particular region? 4) How is social and political organisation reflected in cemeteries? The Bronze Age settlement history of the Százhalombatta area was investigated as part of an international research project

ARQUEOLOGÍA DE JAUJA, PERÚ: DEL INTERMEDIO TEMPRANO AL INTERMEDIO TARDÍO (Resultados de la temporada de campo 1986)

Las investigaciones arqueológicas llevadas a cabo en 1988 fueron diseñadas para examinar a los Sausa, un grupo cultural pre inka, conocido con el nombre de Wanka, asentado en las serranías de los Andes Centrales del Perú

SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues

Variability in SARS-CoV-2 susceptibility and COVID-19 disease severity between individuals is partly due to genetic factors. Here, we identify 4 genomic loci with suggestive associations for SARS-CoV-2 susceptibility and 19 for COVID-19 disease severity. Four of these 23 loci likely have an ethnicity-specific component. Genome-wide association study (GWAS) signals in 11 loci colocalize with expression quantitative trait loci (eQTLs) associated with the expression of 20 genes in 62 tissues/cell types (range: 1:43 tissues/gene), including lung, brain, heart, muscle, and skin as well as the digestive system and immune system. We perform genetic fine mapping to compute 99% credible SNP sets, which identify 10 GWAS loci that have eight or fewer SNPs in the credible set, including three loci with one single likely causal SNP. Our study suggests that the diverse symptoms and disease severity of COVID-19 observed between individuals is associated with variants across the genome, affecting gene expression levels in a wide variety of tissue types

Black-belt diamonds : gems from the speeches, addresses, and talks to students of Booker T. Washington, principal of Tuskegee Institute, Tuskegee, Ala. /

Mode of access: Internet.will digitizeManuscript, Archives, and Rare Book Library copy has "Literary Note." tipped in; from the collection of Randall K. Burkett.The online edition of this book in the public domain, i.e., not protected by copyright, has been produced by the Emory University Digital library Publications Progra

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

Abstract Background For novel cancer treatments, effectiveness in clinical practice is not always aligned with clinical efficacy results. As such it is important to understand a treatment’s real-world effectiveness. We examined real-world population-based comparative effectiveness of second-line ipilimumab versus non-ipilimumab treatments (chemotherapy or targeted treatments). Methods We used a cohort of melanoma patients receiving systemic treatment for advanced disease since April 2005 from Ontario, Canada. Patients were identified from provincial drug databases and the Ontario Cancer Registry who received second-line ipilimumab from 2012 to 2015 (treated) or second-line non-ipilimumab treatment prior to 2012 (historical controls). Historical controls were chosen, to permit the most direct comparison to pivotal trial findings. The cohort was linked to administrative databases to identify baseline characteristics and outcomes. Kaplan-Meier curves and multivariable Cox regression models were used to assess overall survival (OS). Observed potential confounders were adjusted for using inverse probability of treatment weighting (IPTW). Results We identified 329 patients with metastatic melanoma (MM) who had received second-line treatments (189 treated; 140 controls). Patients receiving second-line ipilimumab were older (61.7 years vs 55.2 years) compared to historical controls. Median OS were 6.9 (95% CI: 5.4–8.3) and 4.95 (4.3–6.0) months for ipilimumab and controls, respectively. The crude 1-year, 2-year, and 3-year OS probabilities were 34.3% (27–41%), 20.6% (15–27%), and 15.2% (9.6–21%) for ipilimumab and 17.1% (11–23%), 7.1% (2.9–11%), and 4.7% (1.2–8.2%) for controls. Ipilimumab was associated with improved OS (IPTW HR = 0.62; 95% CI: 0.49–0.78; p < 0.0001). Conclusions This real-world analysis suggests second-line ipilimumab is associated with an improvement in OS for MM patients in routine practice